Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote

Confluent shares nudged 0.1% higher to $30.37 Thursday afternoon following the company’s update on shareholder litigation connected to its upcoming IBM acquisition. The stock fluctuated between $30.35 and $30.56, with about 58 million shares traded.

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck & Co shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio,” Chief Executive Robert M. Davis said. Merck.com
1 2 3 4 7